China’s Biopharma Firm Gan & Lee Teams Up With Novartis In Global Insulin Push

Login to View

Gan & Lee Pharmaceuticals, a biopharmaceutical company specializing in insulin and insulin analogues in China, announced that it has entered into an agreement to commercialize three insulin analogs to Sandoz, a division of Swiss drugmaker Novartis with a focus on biosimilar pharmaceuticals.

Continue reading with a China Money Network subscription


Join Now

Already have an account or paid subscription? Log in


RELATED NEWS